Baxter(US:BAX) Prnewswire·2025-11-14 14:49Core Points - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the Novum LVP medical device, which reportedly suffered from systemic defects leading to serious patient risks [3][4] - The lawsuit claims that Baxter was aware of multiple malfunctions and injuries associated with the Novum LVP but failed to adequately address these issues, resulting in a significant drop in stock price following the announcement of a pause in shipments [4] Summary by Category Company Overview - Baxter International Inc. is a publicly traded company listed on the NYSE under the ticker BAX [3] Legal Issues - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose critical information about the Novum LVP, including systemic defects that caused malfunctions such as underinfusion and overinfusion [3] - Baxter's attempts to mitigate these issues through customer alerts were deemed inadequate, leading to a heightened risk of product recalls and a complete halt in new sales [3] Stock Performance - Following the announcement on July 31, 2025, regarding the voluntary pause of Novum LVP shipments, Baxter's stock price fell by 22.4%, closing at $21.76 [4] Class Action Details - The deadline for investors to seek the role of lead plaintiff in the class action is December 15, 2025 [1] - Faruqi & Faruqi, LLP is encouraging investors who suffered losses to contact them for legal options [1][5]